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T he HLA antigen system, also known as the human major histocompatibility complex, is intimately in­volved in immune responsiveness because these cell surface molecules present amigenic pep tides to the immune system for recognition of self and non-self, 
and also control the development of the T -lymphocyte repertoire 
[1]. As in other immune-mediated diseases [2], the HLA antigens 
associated with alopecia areata (AA) could influence the patient's 
ability to respond to immune challenge and may offer clues to the 
etiology, prognosis, and potential therapy of the disease. Multiple 
HLA class I and class II antigen associations have been described for 
alopecia areata (AA) [3-5]. No consensus has been attained for an 
HLA class I association, but studies of the associations of HLA class 
II antigens with AA have indicated that the antigens HLA-DR4, 
DRS , and DQ3 are found with elevated frequency in AA patients 
compared ,vith normal control frequencies in diverse populations. 
In this study , we have focused on patients with long-standing 
disease. Our objective was to determine which HLA class II 
antigens are associated with two forms of long-standing AA, i.e., 
long-standing patchy alopecia areata (AA) and long-standing alo­
pecia totalis/alopecia universalis (AT I AU), and to examine other 
factors, such as age of onset of disease and familial and patient 
histories of AA, for correlation with the two patient groups. 
MATERIALS AND METHODS 
The study included 131 patients divided into three groups : group I, patients 
newly diagnosed within the previous six months with any extent of alopecia 
areata (n = 31); group II, long-standing patchy alopecia areata (AA) of 
greater than 18 months' duration ,vith greater than 25% hair loss but never 
AT/AU (n = 42); group III, long-standing AT or AU for more than 2 years 
at some point in their lives, with AT/AU defined as 100% scalp hair loss 
with or without body hair loss for 2 years or longer (n = 58). In group II, 
the duration of AA ranged from 18 months to 27 years with a mean of 8 
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years. In group III, the duration of AT/AU ranged from 2 to 54 years with 
a mean of 17 years . All patients were Caucasian and 18 years or older. 
Patients were typed for HLA class I and class II antigens by standard 
complement-dependent serologic methods and were typed for the 
subtypes of the HLA class II antigens by molecnlar method" namely , 
sequence-specific priming (SSP) and sequence-specific oligonucleotide 
probing (SSOP). Statistical analysis was performed by chi-square analysis 
of two-by-two contingency tables. We applied a stringent correction 
factor to the p values obtained as is appropriate for analysis of HLA and 
disease data [2]. p values were corrected by the product of the number 
of antigens typed for times the number of comparisons made. DR and 
DQ p values were corrected for 15 DR-DQ antigens times two 
comparisons (for groups II and III), and DRB1 and DQB1 allele p values 
were corrected for 63 possible DRB1 and DQB1 locus alleles times two 
comparisons = 126. 
As controls, we have utilized population data published in the proceed­
ings of the 11th International Histocompatibility Workshop , Yokohama, 
Japan [6] as controls for HLA class I and II antigen and gene frequencies in 
North American Caucasians. 
Patient demographic data were gathered from all patients and included 
age of onset of the fmt patch of AA and family incidence of AA. 
RESULTS 
Table I shows a summary of the results of the serologic and 
molecular HLA typing of31 group 1,42 group II, and 58 group III 
patients. In addition, all 131 patients were combined into a single 
group referred to as "all patients." The frequency of DRll is 
significantly increased uniquely in group III patients, 43.1 % com­
pared to control 18.5% (Pcor = 2.4 X 10-4). The frequency of the 
generic DQ antigen, DQ3, is significantly increased in both group 
II and group III patients and also in the group composed of all 
patients, 76.2% (Pcor = 0.03),86.2% (Pcor = 9 X 10-6), and 78.6% 
(Pcor = 6 X 10-7), respectively, compared with controls of 48.7%. 
Only in group I does DQ3 fail to achieve statistical significance 
when p values are corrected . 
Recent advances in typing of DNA for HLA antigens have vastly 
improved the accuracy of antigen identification and permitted the 
subtyping of the basic alleles many of which are undetectable by 
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Table I. HLA Antigens with Significantly Elevated Frequencies in Alopecia Areata Patients 
Group Description n 
All patients All patients combined 131 
Group I Newly diagnosed 31 
Group II Long-standing patchy AA 42 
Group III Long-standing AT/AU 58 
1I Pune = P uncorrected. 
b Pear = P corrected by factor of 30 for serologic antigens and 126 for molecular alleles. 
classical serologic methods. For group II patients, there were no 
DRBl alleles found to occur with significantly altered frequencies 
compared with controls when the appropriate correction factor was 
applied to the p values. In group III patients, the most striking 
increase in frequency was that of the DRll subtype, DRB 1 * 11 04, 
which was found in 13.7% (Peor = 6 X 10-13, relative risk = 30.2) 
of group III patients versus 0.5% in controls . A second DR allele, 
DRB1*0401, was increased to 19.6% (Peo, = 0.002) in group III 
patients compared with controls of 6.6%. Group III is also unique in 
the highly significant elevation of frequency of the DQB1 allele, 
DQB1 *0301, the molecular equivalent of DQ7, with a frequency 
of 40.2% (Peor = 1.3 X 10-5) compared with 16.0% in controls . 
Both group II and group III show an increase in the frequency of 
DQB1 *03 (a combination of the incidence of the three alleles, 
DQB1 *0301, *0302, and *0303): group II frequency is 51.6% (Pem 
= 9.4 X 10-4); group III is 55.9% (Pem = 8.1 X 10-8) compared 
with 24.1 % in controls. Thus, DQB 1 *03 may be a general marker 
allele for alopecia areata. 
A very early age of onset of the first patch of AA was found in 
group III patients : by age 10 years, 45% of patients in group III 
developed their first patch of AA as compared with only 10% of 
group II patients. However, by the age of 40 years the majority of 
both group II and group III patients had their first patch of AA: 96% 
of group III patients and 77% of group II patients. Age of onset also 
correlated with the family history of AA: 37% of patients who 
developed their first patch of AA by age 30 years had family 
members with AA whereas only 7.1% of patients had family 
histories of AA when the first patch appeared after age 30. From all 
these data, it appears that early onset of AA is associated with 
severity of disease, long-standing disease, and familial history of AA. 
We hypothesize that failure in some previous studies to 
achieve significance for DR and DQ antigens after appropriate 
statistical correction could be due in part to the inappropriate 
grouping of patients or to the conglomeration of all patients into 
Antigen Pune 
a 
Pear 
b 
DQ3 2.0 X 10-8 6.0 X 10-7 
None 
DQ3 1.0 X 10-3 3.0 X 10-2 
DQBl *03 7.4 X 10-6 9.4 X 10-4 
DQ3 2.6 X 10-7 9.0 X 10-6 
DQBl *03 6.4 X 10-10 8.1 X 10-8 
DQB1*0301 1.0 X 10-7 1.3 X 10-5 
DRB1 *0401 2.0 X 10-5 2.0 X 10-3 
DR11 8.0 X 10-5 2.4 X 10-4 
DRB1 *1104 4.8 X 10-15 6.0 X 10-13 
a single stud y group. In support of this hypothesis, we show that 
a heterogeneous group of newly d iagnosed alopecia areata 
patients , group I, fails to show any HLA associations (Pem 
>0.05). When all the patient groups were lumped together for 
analysis ("all patients ") , a significant association was found for 
only a single HLA antigen , DQ3. 
In conclusion , the two clinical forms of alopecia areata, long­
standing AT/AU, and long-standing patchy AA, can be distin­
guished by the singular association of AT/AU patients with the 
HLA class II antigens DRB1 *1104 (DR11) and DQB1 *0301 
(DQ7). These antigens may represent a genetic marker for those 
patients who are more susceptible to severe and long-lasting 
disease. In addition, 79% of all patients showed an association with 
the generic antigen DQB1 *03 (DQ3), which may represent a 
generalized susceptibility gene for alopecia areata. 
This work was s"ppO/ted ill Palt by granls jimn The Upjohn CompallY. 
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